Ligand Pharmaceuticals LGND
Valuation
Multiples measured against the stock's own five-year history
Near the top of its 5-year range · 99th percentile, 5-year average -2.0x
#2869 of 2994 stocks by PE (1 = cheapest)
Near the top of its 5-year range · 99th percentile, 5-year average 2.8x
#4634 of 5331 stocks by PB (1 = cheapest)
Near the top of its 5-year range · 99th percentile, 5-year average 11.3x
#4768 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 6.42 | – | 2.80 | 99% (pricier than usual) | #4634 of 5331 (1 = cheapest) |
| PE | 124.01 | 68.95 | -1.95 | 99% (pricier than usual) | #2869 of 2994 (1 = cheapest) |
| PS | 24.33 | 17.63 | 11.29 | 99% (pricier than usual) | #4768 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on LGND.
Sign in to join the discussion.